Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

Kevetrin results were not what many here falsely characterized. The recent phase 2 met all endpoints and outcomes. It even confirmed the need for a pill form to extend systemic exposure for a drug with a very short half-life. Further, many wrongly asserted the need for starting from zero, when, in fact, there will be a quick bridge study followed by Phase 2c, optimization and efficacy. With newly acquired increased knowledge of MOA, Phase 2c might even be a drug combination trial. In any case, soon there will be a bottom line data release that will clear up many misperceptions and false assertions.